Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of vorinostat when given
together with bevacizumab and to see how well they work in treating patients with
unresectable or metastatic kidney cancer. Vorinostat may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells
to grow and spread. Others find tumor cells and help kill them or carry tumor-killing
substances to them. Bevacizumab may also stop the growth of kidney cancer by blocking blood
flow to the tumor. Giving vorinostat together with bevacizumab may kill more tumor cells.